Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 79 clinical trials
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer

This phase II trial studies the how well berzosertib and irinotecan work in treating patients with gastric or gastroesophageal junction cancer that is growing, spreading or getting worse (progressive), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Berzosertib may stop the growth …

  • 1 views
  • 19 Sep, 2022
  • 15 locations
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CYH33 in combination with olaprib in patients with DDR gene mutations and/or PIK3CA mutations, in patients who have progressed on prior PARP inhibitor, and in patients with recurrent high grade serous ovarian, fallopian tube, or …

measurable disease
cancer antigen 125
cancer of the ovary
PIK3CA
ovarian cancer
  • 5 views
  • 19 Feb, 2021
  • 1 location
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

The study propose to generate a clinical trial based on precision medicine to evaluate the use of immunotherapy in patients with altered homologous recombination repair genes and without progression after prior targeted therapy.

  • 0 views
  • 31 May, 2021
  • 8 locations
Talazoparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

Background People with advanced cancer are usually treated with surgery, radiation, immunotherapy drugs, or chemotherapy drugs. Talazoparib is a type of drug called a PARP inhibitor. It prevents DNA repair and has shown anticancer activity in early clinical trials. Researchers want to learn more about how it works in different …

  • 0 views
  • 13 Jan, 2021
  • 1 location
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance Niraparib regimen in patients with advanced or platinum sensitive …

serous adenocarcinoma
follicle stimulating hormone
hysterectomy
neutrophil count
niraparib
  • 128 views
  • 05 Aug, 2021
  • 1 location
Genotyping 2 SNPs in Chinese Breast Cancers

The purpose of this study is to determine the frequency of two Single Nucleotide Polymorphisms (SNPs) by sanger-sequencing in Breast Cancers and healthy controls .

Accepts healthy volunteers
  • 0 views
  • 26 Mar, 2022
  • 1 location
Strategic Targeting for Optimal Prevention of Cancer (STOP-Cancer)

The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early detection and treatment …

  • 14 views
  • 09 Feb, 2022
  • 1 location
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of …

TP53
BRCA2
fallopian tube
cancer of the ovary
PTEN
  • 22 views
  • 15 Sep, 2022
  • 1 location
Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2

To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1/2 variants.

BRCA2
fallopian tube
BRCA1/2
BRCA1
cancer
  • 9 views
  • 08 Apr, 2021
  • 2 locations
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (PROGECT)

PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).

triple negative breast cancer
BRCA2
Accepts healthy volunteers
PTEN
BRCA1
  • 22 views
  • 26 Apr, 2022
  • 13 locations